Claims
- 1. A compound S 31794/F-1 having the following characteristics:
- .lambda..sub.MAX 194 nm E.sub.1 cm.sup.1% =807,
- .lambda..sub.MAX 225 nm (shoulder) E.sub.1 cm.sup.1% =132,
- .lambda..sub.MAX 276 nm E.sub.1 cm.sup.1% =12.8,
- .lambda..sub.MAX 284 nm (shoulder) E.sub.1 cm.sup.1% =10.5, (see FIG. 1);
- .sup.1 H NMR spectrum in deuterated DMSO (100 megacycles per second second) with tetramethylsilane as internal standard (see FIG. 4);
- .sup.13 C NMR spectrum in deuterated methanol (D.sub.4) with tetramethylsilane as internal standard (see Table 1);
- and having the following additional characteristics in amorphous form;
- elementary analysis: C 53.9%, H 7.5%, N 10.1%, O 27.3%; IR spectrum in kBr (see FIG. 2);
- and having the following additional characteristics in crystalline form:
- elementary analysis: C 55.5-56.5%, H 7.5-7.7%, N 10.5-10.8%, O 26.5-27.0%; IR spectrum in Nujol (see FIG. 3).
- 2. The compound of claim 1 in amorphous form.
- 3. The compound of claim 1 in crystalline form.
- 4. A process for the production of an antibiotic S 31794/F-1 having the following characteristics:
- UV spectrum in methanol:
- .lambda..sub.MAX 194 nm E.sub.1 cm.sup.1% =807,
- .lambda..sub.MAX 225 nm (shoulder) E.sub.1 cm.sup.1% =132,
- .lambda..sub.MAX 276 nm E.sub.1 cm.sup.1% =12.8,
- .lambda..sub.MAX 284 nm (shoulder) E.sub.1 cm.sup.1% =10.5, (see FIG. 1);
- .sup.1 H NMR spectrum in deuterated DMSO (100 megacycles per second second) with tetramethylsilane as internal standard (see FIG. 4);
- .sup.13 C NMR spectrum in deuterated methanol (D.sub.4) with tetramethylsilane as internal standard (see Table 1);
- and having the following additional characteristics in amorphous form:
- elementary analysis: C 53.9%, H 7.5%, N 10.1%, O 27.3%; IR
- spectrum in kBr (see FIG. 2);
- and having the following additional characteristics in crystalline form;
- elementary analysis: C 55.5-56.5%, H 7.5-7.7%, N 10.5-10.8%, O 26.5-27.0%; IR spectrum in Nujol (see FIG. 3);
- which comprises cultivating the strain NRRL 8095 of Acrophialophora limonispora nov. spec. Dreyfus+Muller under aerobic fermentation conditions in a nutrient medium until a sufficient amount of antibiotic S 31794/F-1 is produced.
- 5. A pharmaceutical composition for treating Candida albicans comprising a Canadida albicans inhibiting effective amount of a compound of claim 1 in association with a pharmaceutical carrier or diluent.
- 6. A method of combatting Candida albicans infections in animals which comprises administering a Candida albicans inhibiting effective amount of a compound of claim 1 to an animal in need of such treatment.
Priority Claims (1)
Number |
Date |
Country |
Kind |
8894/75 |
Jul 1975 |
CHX |
|
Parent Case Info
This is a continuation, of application Ser. No. 702,210 filed July 2, 1976 which is now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3843784 |
Hamill et al. |
Oct 1974 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
702210 |
Jul 1976 |
|